Evidence map›Paper›PMID 25022514›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2014

Targeted injection of a biocomposite material alters macrophage and fibroblast phenotype and function following myocardial infarction: relation to left ventricular remodeling.

Jeremy R McGarvey, Sara Pettaway, James A Shuman, Craig P Novack, Kia N Zellars, Parker D Freels, Randall L Echols, Jason A Burdick, Joseph H Gorman, Robert C Gorman and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. ModulatingJournal of materials chemistry. B · 2016
    Article
  12. UM206, a selective Frizzled antagonist, attenuates adverse remodeling after myocardial infarction in swine.Laboratory investigation; a journal of technical methods and pathology · 2016
    Article
  13. Developing injectable nanomaterials to repair the heart.Current opinion in biotechnology · 2015
    Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jeremy R McGarveyCardiovascular Translational Research Center, University of South Carolina School of Medicine and the WJB Dorn Veteran Affairs Medical Center, Columbia, South Carolina (S.P., J.A.S., C.P.N., K.N.Z., P.D.F., R.L.E., F.G.S.); and Department of Bioengineering (J.A.B.) and Gorman Cardiovascular Research Group, Department of Surgery (J.R.M., J.H.G., R.C.G.), University of Pennsylvania, Philadelphia, Pennsylvania.
Sara PettawayCardiovascular Translational Research Center, University of South Carolina School of Medicine and the WJB Dorn Veteran Affairs Medical Center, Columbia, South Carolina (S.P., J.A.S., C.P.N., K.N.Z., P.D.F., R.L.E., F.G.S.); and Department of Bioengineering (J.A.B.) and Gorman Cardiovascular Research Group, Department of Surgery (J.R.M., J.H.G., R.C.G.), University of Pennsylvania, Philadelphia, Pennsylvania.
James A ShumanCardiovascular Translational Research Center, University of South Carolina School of Medicine and the WJB Dorn Veteran Affairs Medical Center, Columbia, South Carolina (S.P., J.A.S., C.P.N., K.N.Z., P.D.F., R.L.E., F.G.S.); and Department of Bioengineering (J.A.B.) and Gorman Cardiovascular Research Group, Department of Surgery (J.R.M., J.H.G., R.C.G.), University of Pennsylvania, Philadelphia, Pennsylvania.
Craig P NovackCardiovascular Translational Research Center, University of South Carolina School of Medicine and the WJB Dorn Veteran Affairs Medical Center, Columbia, South Carolina (S.P., J.A.S., C.P.N., K.N.Z., P.D.F., R.L.E., F.G.S.); and Department of Bioengineering (J.A.B.) and Gorman Cardiovascular Research Group, Department of Surgery (J.R.M., J.H.G., R.C.G.), University of Pennsylvania, Philadelphia, Pennsylvania.
Kia N ZellarsCardiovascular Translational Research Center, University of South Carolina School of Medicine and the WJB Dorn Veteran Affairs Medical Center, Columbia, South Carolina (S.P., J.A.S., C.P.N., K.N.Z., P.D.F., R.L.E., F.G.S.); and Department of Bioengineering (J.A.B.) and Gorman Cardiovascular Research Group, Department of Surgery (J.R.M., J.H.G., R.C.G.), University of Pennsylvania, Philadelphia, Pennsylvania.
Parker D FreelsCardiovascular Translational Research Center, University of South Carolina School of Medicine and the WJB Dorn Veteran Affairs Medical Center, Columbia, South Carolina (S.P., J.A.S., C.P.N., K.N.Z., P.D.F., R.L.E., F.G.S.); and Department of Bioengineering (J.A.B.) and Gorman Cardiovascular Research Group, Department of Surgery (J.R.M., J.H.G., R.C.G.), University of Pennsylvania, Philadelphia, Pennsylvania.
Randall L EcholsCardiovascular Translational Research Center, University of South Carolina School of Medicine and the WJB Dorn Veteran Affairs Medical Center, Columbia, South Carolina (S.P., J.A.S., C.P.N., K.N.Z., P.D.F., R.L.E., F.G.S.); and Department of Bioengineering (J.A.B.) and Gorman Cardiovascular Research Group, Department of Surgery (J.R.M., J.H.G., R.C.G.), University of Pennsylvania, Philadelphia, Pennsylvania.
Jason A BurdickCardiovascular Translational Research Center, University of South Carolina School of Medicine and the WJB Dorn Veteran Affairs Medical Center, Columbia, South Carolina (S.P., J.A.S., C.P.N., K.N.Z., P.D.F., R.L.E., F.G.S.); and Department of Bioengineering (J.A.B.) and Gorman Cardiovascular Research Group, Department of Surgery (J.R.M., J.H.G., R.C.G.), University of Pennsylvania, Philadelphia, Pennsylvania.
Joseph H GormanCardiovascular Translational Research Center, University of South Carolina School of Medicine and the WJB Dorn Veteran Affairs Medical Center, Columbia, South Carolina (S.P., J.A.S., C.P.N., K.N.Z., P.D.F., R.L.E., F.G.S.); and Department of Bioengineering (J.A.B.) and Gorman Cardiovascular Research Group, Department of Surgery (J.R.M., J.H.G., R.C.G.), University of Pennsylvania, Philadelphia, Pennsylvania.
Robert C GormanCardiovascular Translational Research Center, University of South Carolina School of Medicine and the WJB Dorn Veteran Affairs Medical Center, Columbia, South Carolina (S.P., J.A.S., C.P.N., K.N.Z., P.D.F., R.L.E., F.G.S.); and Department of Bioengineering (J.A.B.) and Gorman Cardiovascular Research Group, Department of Surgery (J.R.M., J.H.G., R.C.G.), University of Pennsylvania, Philadelphia, Pennsylvania.
Francis G SpinaleCardiovascular Translational Research Center, University of South Carolina School of Medicine and the WJB Dorn Veteran Affairs Medical Center, Columbia, South Carolina (S.P., J.A.S., C.P.N., K.N.Z., P.D.F., R.L.E., F.G.S.); and Department of Bioengineering (J.A.B.) and Gorman Cardiovascular Research Group, Department of Surgery (J.R.M., J.H.G., R.C.G.), University of Pennsylvania, Philadelphia, Pennsylvania cvctrc@uscmed.sc.edu.
University of Pennsylvania · USUniversity of South Carolina · US

Funding

Multidisciplinary Training in Cardiovascular BiologyT32HL007954 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI DAVIES, PETER FRANCIS · 2000 to 2019
$9.9M
Surgery to Prevent Post Infarction Ventricular RemodelingR01HL063954 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI GORMAN, ROBERT C · 2001 to 2018
$9.8M
Localized Targeting of Matrix Proteases Following Myocardial InfarctionR01HL111090 · NHLBI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI BURDICK, JASON A, SPINALE, FRANCIS G · 2012 to 2015
$2.0M
Myocardial Protection and Matrix ProteasesR01HL095608 · NHLBI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI SPINALE, FRANCIS G · 2010 to 2013
$1.4M
Reversal of Myocardial Infarction by Localized StimulationR42HL112519 · NHLBI · MICRO VIDE, LLC · PI SPINALE, FRANCIS G · 2013 to 2015
$1.2M
Maladaptive Remodeling in Aging MyocardiumI01BX000168 · VA · VETERANS HEALTH ADMINISTRATION · PI SPINALE, FRANCIS G · 2009 to 2024
–
BLRD VA I01 BX000168NHLBI NIH HHS HL063954NHLBI NIH HHS HL095608NHLBI NIH HHS HL111090NHLBI NIH HHS R01 HL063954NHLBI NIH HHS R01 HL095608NHLBI NIH HHS R01 HL111090NHLBI NIH HHS R42 HL112519NHLBI NIH HHS T32 HL007954NHLBI NIH HHS T32-HL007954
6 · The paper itself

Abstract

A treatment target for progressive left ventricular (LV) remodeling prevention following myocardial infarction (MI) is to affect structural changes directly within the MI region. One approach is through targeted injection of biocomposite materials, such as calcium hydroxyapatite microspheres (CHAM), into the MI region. In this study, the effects of CHAM injections upon key cell types responsible for the MI remodeling process, the macrophage and fibroblast, were examined. MI was induced in adult pigs before randomization to CHAM injections (20 targeted 0.1-ml injections within MI region) or saline. At 7 or 21 days post-MI (n = 6/time point per group), cardiac magnetic resonance imaging was performed, followed by macrophage and fibroblast isolation. Isolated macrophage profiles for monocyte chemotactic macrophage inflammatory protein-1 as measured by real-time polymerase chain reaction increased at 7 days post-MI in the CHAM group compared with MI only (16.3 ± 6.6 versus 1.7 ± 0.6 cycle times values, P < 0.05), and were similar by 21 days post-MI. Temporal changes in fibroblast function and smooth muscle actin (SMA) expression relative to referent control (n = 5) occurred with MI. CHAM induced increases in fibroblast proliferation, migration, and SMA expression-indicative of fibroblast transformation. By 21 days, CHAM reduced LV dilation (diastolic volume: 75 ± 2 versus 97 ± 4 ml) and increased function (ejection fraction: 48 ± 2% versus 38 ± 2%) compared with MI only (both P < 0.05). This study identified that effects on macrophage and fibroblast differentiation occurred with injection of biocomposite material within the MI, which translated into reduced adverse LV remodeling. These unique findings demonstrate that biomaterial injections impart biologic effects upon the MI remodeling process over any biophysical effects.

Indexed as

Disease Models, AnimalAnimalsBiocompatible MaterialsDrug Delivery SystemsDurapatiteFibroblastsHeart VentriclesInjectionsMacrophagesMicrospheresMyocardial InfarctionPhenotypeRandom AllocationSwineVentricular RemodelingBiocompatible MaterialsDurapatite

Identifiers

PMID25022514
PMCPMC4152878
OpenAlexW2169481518

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.